Pathios Therapeutics
Pathios is a clinical-stage oncology and immunology company that targets a unique and genetically validated immune cell receptor, the acid-sensing GPRC65, that has the potential to revolutionise oncology treatment across multiple solid tumour types.
Therapeutic Area:
Immuno-OncologyOncology
US $58m
Funding: Series B 2024
2017
Year Founded
Unmet Need and Commercial Potential
Cancer remains the number one most deadly disease of humans globally with approximately 10 million deaths per year. Pathios Therapeutics is pioneering a first-in-class approach that targets GPR65—a genetically validated immune receptor that drives immune suppression in the acidic tumour microenvironment.
By inhibiting GPR65, Pathios aims to restore immune function and unlock new treatment potential across multiple cancer types, offering renewed hope to patients and their families.
10 million
Cancer deaths per year globally.
Targeting GPR65 to reprogram immune cells and transform cancer treatment.
Syndicate Investors
